Sionna Therapeutics Cuts 46% of Workforce After Cystic Fibrosis Trial Failure
NewsData.io · United States · Sep 15, 2026
Sionna Therapeutics is laying off approximately 46% of its workforce — roughly 27 employees based on a year-start headcount of 59 — following the failure of its lead cystic fibrosis program. The company will redirect resources toward a phase 2a study of a new dual-combination therapy. Chief Business Officer Caroline Stark Beer is among those departing, and the restructuring is expected to cost $6.4 million while extending cash runway into the second half of 2029.
Get the weekly brief by email
What changed in staffing last week, every Monday morning. Free. Unsubscribe anytime.
Related stories
Sionna Therapeutics (NASDAQ: SION) eliminated approximately 46% of its workforce in September as part of a strategic pivot to focus exclusively on a…
Detroit ABC affiliate WXYZ-TV (Channel 7) has eliminated at least 30 positions through a combination of buyouts and layoffs, according to sources who…
Dole Packaged Foods will permanently close its Atwater, California processing facility and a nearby Livingston laboratory, eliminating 404 jobs in…
About 1,400 IRS IT employees displaced by DOGE-directed downsizing have been reorganized into 'ONE IRS Readiness' teams with no defined mission…